Latest News & Features
Europe
Transatlantic deal would make ‘HSF Kramer’ a top 20 global firm by revenue | ‘Transformational’ combination a ‘one-of-a-kind’ opportunity, say firms’ leaders | HSF Kramer would have 2,700 lawyers, including 640 partners across 25 offices | IP practice would have approximately 32 partners. 14 November 2024
Americas
Oral arguments heard in case between Teva and generics maker Amneal over inhaler patents | Teva says district court and Amneal asked court to ‘slice apart new drug application’. 12 November 2024
Europe
The patents have been officially revoked following the pair's voluntary decision to withdraw them | Withdrawal follows unfavourable preliminary opinion from the EPO | Cancelled patents not expected to impact ongoing licensing agreements for CRISPR technology, says licensor. 12 November 2024
Careers
Sapna Palla joins the firm in New York, bringing significant experience in complex life sciences and IP disputes to a growing practice. 12 November 2024
Americas
As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office. 7 November 2024
Asia
Free trade zones in Beijing, Shanghai, Guangdong, and Hainan are designed to attract capital into China’s fast-growing healthcare sectors, says Li Mi of Lusheng. 7 November 2024
Americas
Well-drafted contracts and ironclad tech security can save time and money when an ex-employee steals IP ‘like sugar packets in Starbucks’, finds Tom Phillips. 7 November 2024
Americas
A US biopharma firm must pay the damages to Sandoz over a long-running dispute over lung therapy | New Jersey district judge had ordered the pair to “meet and confer” in a September judgment, but the parties couldn’t agree. 5 November 2024
Americas
The 47th US president will need to address the thorny issues of non-competes, patent rights and drug pricing. 5 November 2024
Americas
A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | Case stemmed from a previous arbitration involving the chief scientific officer of Inhibrx | Jury found no evidence supporting opponents claims, awarding the plaintiff $0 damages. 5 November 2024